Vinci Pharmaceuticals Secures $8.5 Million to Advance EPIPLANT™ Drug Delivery Platform

Vinci Pharmaceuticals Inc., a specialty ophthalmic pharmaceutical company, has secured an additional $8.5 million in funding, bringing its total raised to more than $16.5 million. This latest Series A financing round will support the company’s efforts in manufacturing, testing, and releasing its EPIPLANT™ drug delivery platform, which is designed to address the limitations of intraocular injections.

Developed by Karl Csaky, MD, PhD, and licensed from the Retina Foundation of the Southwest in Dallas, Texas, EPIPLANT™ is a proprietary episcleral implant platform that provides sustained drug delivery to retinal tissues. The company plans to initiate a Phase 1/2a clinical study in 2027 to evaluate the safety and efficacy of the EPIPLANT™ VCI-002 product. Vinci Pharmaceuticals is working closely with its scientific advisory board of physicians to ensure the program’s success.

Sarah Hassan, Managing Director at Dynagrow Capital, expressed her excitement about the potential of EPIPLANT™.

The company has been granted multiple patents covering its proprietary EPIPLANT™ technology and has completed preliminary preclinical testing. Vinci Pharmaceuticals plans to initiate a first-in-human Phase 1/2a clinical trial in 2027. The EPIPLANT™ technology is designed to address the limitations of current drug delivery approaches for retinal diseases, which often require administration directly into the eye or face challenges in achieving effective drug concentrations in retinal tissues.

Vinci Pharmaceuticals Inc. is a clinic-ready ophthalmic company leveraging a novel, proprietary platform to develop first-, best- and only-in-class products with differentiated profiles to treat certain diseases of the retina. The company’s focus on innovative drug delivery systems aims to improve patient outcomes and simplify treatment processes for both patients and healthcare providers. The financing was led by Dynagrow Capital, LLLP, with support from MintPharma Capital. Proceeds from the financing are expected to support GMP manufacturing, testing and release activities of the EPIPLANT™ VCI-002 product, and the Phase 1/2a study in 2027.

This funding round underscores the company’s commitment to advancing its EPIPLANT™ platform and bringing new treatment options to patients suffering from retinal diseases. Vinci Pharmaceuticals Inc. continues to work towards transforming the treatment landscape for sight-threatening diseases through its innovative drug delivery technology.